Date: 14 Mar 2012
Ligustrazine Phosphate Ethosomes for Treatment of Alzheimer’s Disease, In Vitro and in Animal Model Studies
In the present study, we have investigated transdermal administration of ligustrazine phosphate (LP), as an antioxidant, for the treatment of Alzheimer’s disease (AD). The LP transdermal ethosomal system was designed and characterized. Franz-type diffusion cells and confocal laser scanning microscopy were used for the in vitro permeation studies. Furthermore, the effect of LP transdermal ethosomal system on AD was evaluated in the scopolamine-induced amnesia rats by evaluating the behavioral performance in the Morris water maze test. The activities of the antioxidant enzymes and the levels of the lipid peroxidation product malondialdehyde (MDA) in the brain of rats were also determined. The results showed that both the penetration ability and the drug deposition in skin of the LP ethosomal system were significantly higher than the aqueous one. The LP transdermal ethosomal system could recover the activities of the antioxidant enzymes and the levels of MDA in the brain of the amnesic rats to the similar status of the normal rats, which was also indirectly reflected by the improvement in the behavioral performance. In conclusion, LP might offer a potential alternative therapeutic drug in the fight against AD, and ethosomes could be vesicles of choice for transdermal delivery of LP.
Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol. 2006;44:1–11.PubMed
Cai Z, Yan Y, Sun S, Zhang J, Huang L, Yan L, et al. Upregulation of BACE1 and β-Amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer’s disease. Neurochem Res. 2009;34:1226–35.CrossRef
Zhang XL, Jiang B, Li ZB, Hao S, An LJ. Catalpol ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by d-galactose. Pharmacol Biochem Behav. 2007;8:64–72.CrossRef
Xu H, Shi DZ. The clinical applications and pharmacologic effects of Ligustrazine. Chin J Integr Tradit West Med. 2003;23:376–7.
Zhang SJ, Wang ZT, Han LH, Chai SB. Effects of tetramethylpyrazine injection on angiogenesis and expression of VEGF mRNA in ischemic myocardium of rats with myocardial infarction. Chin J Exp Tradit Med Formulae. 2011;17:170–3.
Zhao L, Wei MJ, He M, Jin WB, Zhao HS, Yao WF. The effects of tetramethylpyrazine on learning and memory abilities of mice with Alzheimer disease and its possible mechanism. Chin Pharmacol Bull. 2008;24:1088–92.
Wang L, Guo Q, Han J, Zhang Y, Chen X. Pharmacokinetics of ligustrazine in blood, brain, and liver of mice. Chin Tradit Herb Drugs. 2009;40:935–8.
Cai W, Dong SN, Lou YQ. HPLC determination of tetramethylpyrazine in human serum and its pharmacokinetic parameters. Acta Pharmaceut Sin. 1989;24:881–6.
Zeng CY, Mei QX. ADRs induced by tetramethylpyrazine: literature analysis of 30 cases. China Pharm. 2008;19:1908–10.
Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech. 2007;8:191–9.CrossRef
Shen T, Xu H, Weng W, Zhang J. Study on the human pharmacokinetics and relative bioavailability of tetramethylpyrazine phosphate patch. Proceedings of the sixth Chinese pharmaceutical association annual meeting. 2006, Nov 9, Guangzhou, China.
Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;332:60–6.CrossRef
- Ligustrazine Phosphate Ethosomes for Treatment of Alzheimer’s Disease, In Vitro and in Animal Model Studies
Volume 13, Issue 2 , pp 485-492
- Cover Date
- Online ISSN
- Springer US
- Additional Links
- Alzheimer’s disease
- ligustrazine phosphate
- transdermal delivery
- Industry Sectors